Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence
Technology appraisal guidance
Reference number: TA1086
Published:
Tools and resources
Tools and resources to help you put the guidance into practice.